

US PATENT & TRADEMARK OFFICE

PATENT APPLICATION FULL TEXT AND IMAGE DATABASE



Searching PGPUB Production Database March 15th - September 30th 2001...

Results of Search in PGPUB Production Database March 15th - September 30th 2001 for:
AANM/"EMC Global Technologies": 59 applications.
 Hits 1 through 50 out of 59

Final 9 Hits

Jump To

Refine Search

AANM/"EMC Global Technologies"

PUB. APP. NO.	Title
1	20210348240 HEREDITARY CANCER GENES
2	20210310079 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY
3	20210262016 METHODS AND SYSTEMS FOR SOMATIC MUTATIONS AND USES THEREOF
4	20210071269 GENE SIGNATURES FOR CANCER PROGNOSIS
5	20200399713 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY
6	20200283855 METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES FOR PREDICTING CHEMOTHERAPY BENEFIT
7	20200255908 GENES AND GENE SIGNATURES FOR DIAGNOSIS AND TREATMENT OF MELANOMA
8	20200249243 ADJUSTED MULTI-BIOMARKER DISEASE ACTIVITY SCORE FOR INFLAMMATORY DISEASE ASSESSMENT
9	20200239943 METHODS AND MATERIALS FOR ASSESSING ALLELIC IMBALANCE
10	20200190602 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY
11	20200087737 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY
12	20200056246 CANCER BIOMARKERS
13	20200010913 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY
14	20190185939 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY
15	20190153542 CANCER BIOMARKERS
16	20190032144 GENES AND GENE SIGNATURES FOR DIAGNOSIS AND TREATMENT OF MELANOMA
17	20180334722 GENE SIGNATURES FOR CANCER PROGNOSIS
18	20180267041 SIGNATURES FOR PREDICTING CANCER IMMUNE THERAPY RESPONSE
19	20180265930 CANCER BIOMARKERS
20	20180030544 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY
21	20180017580 BIOMARKERS FOR DISTINGUISHING MOOD DISORDERS
22	20170314081 METHODS OF DETECTING CANCER

- 23 [20170283879](#) [METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY](#)
- 24 [20170247768](#) [CANCER BIOMARKERS](#)
- 25 [20170198358](#) [GENES AND GENE SIGNATURES FOR DIAGNOSIS AND TREATMENT OF MELANOMA](#)
- 26 [20170152571](#) [GENE SIGNATURES FOR CANCER PROGNOSIS](#)
- 27 [20170137890](#) [CANCER PROGNOSIS SIGNATURES](#)
- 28 [20170130263](#) [METHODS AND MATERIALS FOR ASSESSING ALLELIC IMBALANCE](#)
- 29 [20170096712](#) [GENE SIGNATURES FOR CANCER DIAGNOSIS AND PROGNOSIS](#)
- 30 [20170022569](#) [METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY](#)
- 31 [20160355884](#) [GENE SIGNATURES FOR CANCER PROGNOSIS](#)
- 32 [20160348183](#) [METHOD FOR PREDICTING THE RESPONSE AND SURVIVAL FROM CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER](#)
- 33 [20160281177](#) [GENE SIGNATURES FOR RENAL CANCER PROGNOSIS](#)
- 34 [20160160294](#) [METHODS AND MATERIALS FOR PREDICTING RESPONSE TO NIRAPARIB](#)
- 35 [20160145681](#) [METHODS AND MATERIALS FOR ASSESSING ALLELIC IMBALANCE](#)
- 36 [20150344966](#) [Hereditary Cancer Diagnostics](#)
- 37 [20150247208](#) [GENE SIGNATURES FOR CANCER PROGNOSIS](#)
- 38 [20150232947](#) [CANCER BIOMARKERS](#)
- 39 [20150177253](#) [TUMOR SUPPRESSOR DESIGNATED TS10Q23.3](#)
- 40 [20150167103](#) [GENE SIGNATURES FOR CANCER PROGNOSIS](#)
- 41 [20150167100](#) [Hereditary Cancer Genes](#)
- 42 [20150159214](#) [DEP2 AND ITS USES IN MAJOR DEPRESSIVE DISORDER AND OTHER RELATED DISORDERS](#)
- 43 [20150094377](#) [HEREDITARY CANCER GENES](#)
- 44 [20150080260](#) [METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY](#)
- 45 [20150018527](#) [METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY](#)
- 46 [20140363521](#) [METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY](#)
- 47 [20140315935](#) [GENE SIGNATURES FOR LUNG CANCER PROGNOSIS AND THERAPY SELECTION](#)
- 48 [20140303001](#) [BLADDER CANCER DETECTION AND MONITORING](#)
- 49 [20140278135](#) [ELECTRONIC VARIANT CLASSIFICATION](#)
- 50 [20140271546](#) [GENES AND GENE SIGNATURES FOR DIAGNOSIS AND TREATMENT OF MELANOMA](#)

